Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Subcutaneous Guadecitabine in Prior Responders
jRCT2080223957Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jun 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of guadecitabine in cancer, sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Safety and tolerability of continued guadecitabine. Started Jun 2018; status: completed.
02
Drugs
guadecitabine
03
Conditions
cancer
Beyond the preview
Go deeper on jRCT2080223957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223957.